Full-Time

Director – Biostatistics

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$205.6k - $292.7k/yr

+ Discretionary Annual Bonus + Discretionary Stock-Based Long-Term Incentives

No H1B Sponsorship

San Mateo, CA, USA + 1 more

More locations: Parsippany-Troy Hills, NJ, USA

Hybrid

Hybrid role; some onsite days required.

US Top Secret Clearance Required

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Biostatistics

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • 12+ Years with bachelor's degree
  • 10+ Years with master’s degree
  • 8 years with PhD
Responsibilities
  • Provide statistical leadership for late-phase Virology clinical development programs, contributing to study design, analysis planning, data interpretation, and evidence generation to support development and regulatory objectives.
  • Opportunity to serve as the Biostatistics Program Lead for Virology programs or major studies, representing the Biostatistics function on cross-functional teams and supporting interactions with Health Authorities as needed.
  • Partner effectively with Statistical Programming, Clinical Development, Data Management, Clinical Operations, Global Patient Safety, Regulatory Affairs, Medical Writing, and Project Management to ensure timely delivery of high-quality analyses, regulatory submissions, and clinical study reports.
  • Apply statistical expertise and regulatory knowledge to support study design, protocol development, statistical analyses, interpretation of clinical trial results, and preparation of regulatory documentation.
  • Provide leadership for statistical activities across assigned clinical studies, ensuring high-quality study design, analysis planning, data review, and regulatory documentation through collaboration with internal teams, external partners, and CROs.
  • Create Inclusion - knowing the business value of diverse teams, modeling inclusion, and embedding the value of diversity in the way they manage their teams.
  • Develop Talent - understand the skills, experience, aspirations and potential of their employees and coach them on current performance and future potential. They ensure employees are receiving the feedback and insight needed to grow, develop and realize their purpose.
  • Empower Teams - connect the team to the organization by aligning goals, purpose, and organizational objectives, and holding them to account. They provide the support needed to remove barriers and connect their team to the broader ecosystem.
Desired Qualifications
  • Demonstrated hands-on experience in clinical drug development, including design, analysis, and interpretation of late-phase clinical trials and support of regulatory submissions.
  • Strong expertise in biostatistics and clinical trial methodology, with proficiency in industry-standard statistical software and application of appropriate statistical methods to support study objectives and decision-making.
  • Good understanding of the biopharmaceutical development process and regulatory environment, with the ability to integrate scientific and regulatory considerations into statistical recommendations.
  • Proven ability to work effectively in cross-functional teams and communicate statistical concepts to a variety of stakeholders, including clinicians, regulatory colleagues, and senior management.
  • Experience leading statistical activities for clinical development programs or major studies, managing multiple priorities, and delivering high-quality results within timelines.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 product sales excluding Veklury rose 10%, and guidance increased to $30.4 billion.
  • Yeztugo reached a $1 billion annual run rate with strong patient retention by August 2026.
  • Anito-cel’s FDA PDUFA date is December 23, 2026, creating a near-term oncology catalyst.

What critics are saying

  • HIV still generated nearly three-quarters of quarterly product sales in Q2 2026.
  • Cell therapy sales fell 14% in Q2 2026, showing Kite faces harsh competition.
  • Arcellx integration cut 192 jobs, signaling execution risk and post-deal disruption through 2027.

What makes Gilead Sciences unique

  • Gilead owns HIV leadership with Biktarvy, Descovy, and Yeztugo driving 2026 growth.
  • The August 2026 Arcellx acquisition strengthens Gilead’s CAR-T position for anito-cel.
  • Gilead’s California Supreme Court victory protects its innovation model across future drug portfolios.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 24th, 2026
Gilead posts $11B loss on pipeline acquisitions despite 10% product sales growth

Gilead Sciences reported strong commercial performance in Q2 2026, with product sales excluding Veklury rising 10% to $7.6 billion. HIV revenue grew 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy at $967 million. Despite this growth, the company posted one of its largest quarterly losses due to over $11 billion in acquired research and development expenses. These acquisitions included Arcellx, which gives Gilead full control of anito-cel, a CAR-T treatment for multiple myeloma pending FDA approval by December 2026. The company raised its 2026 product-sales guidance to $30.1–$30.4 billion. Gilead also reported encouraging progress beyond HIV, with liver-disease revenue up 10% and Trodelvy breast-cancer treatment sales rising 26% to $457 million.

Yahoo Finance
Aug 23rd, 2026
Gilead's HIV sales surge 12% to $5.7B, but franchise accounts for 75% of total revenue

Gilead Sciences reported strong fiscal Q2 2026 results, with total revenue rising 10% year-over-year to approximately $7.8 billion. The growth was primarily driven by its HIV franchise, including Biktarvy and newly launched Yeztugo. HIV product sales rose 12% to $5.7 billion, representing nearly three-quarters of quarterly product sales. Descovy sales increased 48% to $967 million, whilst Biktarvy sales grew 7% to $3.8 billion. Yeztugo generated $232 million, up substantially from $15 million in the prior-year period. The company's liver disease portfolio sales rose 10% to $877 million. However, cell therapy sales declined 14% to $417 million, reflecting competitive pressure. Gilead recorded an $11.2 billion quarterly loss due to acquired research and development expenses, including $7.0 billion for the Arcellx acquisition.

Ticker Report
Aug 18th, 2026
MidFirst Bank Makes New $810,000 Investment in Gilead Sciences, Inc. $GILD

MidFirst Bank acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 6,414 shares of the biopharmaceutical company’s stock, valued at approximately $810,000. A number of other hedge funds and other institutional investors […]

Yahoo Finance
Aug 16th, 2026
Gilead Sciences down 11.3% in six months as revenue growth disappoints at 2.7% CAGR

Gilead Sciences' shares have fallen 11.3% to $137.77 over the past six months, contrasting with the S&P 500's 13.1% gain. The biopharmaceutical company has shown disappointing long-term performance, with revenue growing at just 2.7% annually over five years. The company's profitability metrics have deteriorated significantly. Its adjusted operating margin decreased by 34.2 percentage points over the past five years, landing at 9.7% for the trailing 12 months. Earnings per share declined by 15.4% annually during the same period, indicating reduced profitability as the company expanded. Despite trading at a relatively fair valuation of 14.9× forward price-to-earnings ratio, analysts suggest limited upside potential compared to downside risk.

Yahoo Finance
Aug 13th, 2026
Gilead Sciences beats Q2 estimates with $7.8B revenue as PrEP sales top $1B for first time

Gilead Sciences reported strong Q2 results, with revenue of $7.80 billion, beating analyst estimates of $7.35 billion. The 10.2% year-on-year growth was driven by its HIV franchise, particularly Biktarvy and the PrEP segment, alongside advances in oncology and liver disease treatments. CEO Daniel O'Day highlighted that quarterly PrEP sales doubled year-on-year, exceeding $1 billion for the first time. New product launches, including Trodelvy in breast cancer and Livdelzi in liver disease, contributed to the results. The company raised its full-year revenue guidance to $30.25 billion at the midpoint and increased adjusted EPS guidance by 44.1%. During the earnings call, analysts questioned management about prescription trends, product strategies, revenue diversification, regulatory interactions, and the impact of US insurance changes on Biktarvy's growth.